Thalidomide therapy. An open trial.
In an open trial, 35 patients suffering from a variety of dermatologic conditions were treated with thalidomide. The drug was shown to be a valuable addition to the therapeutic armamentarium; however, the occurrence of a peripheral neuropathy will limit its use just as its teratogenic side effects have done for many years.
Naafs
B
B
Faber
W R
WR
D000328:Adult; D000368:Aged; D002493:Central Nervous System Diseases / Q000139:chemically induced; D004892:Erythema Multiforme / Q000188:drug therapy; D005260:Female; D006801:Humans; D008010:Lichen Planus / Q000188:drug therapy; D008179:Lupus Erythematosus, Discoid / Q000188:drug therapy; D008177:Lupus Vulgaris / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010391:Pemphigoid, Bullous / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011536:Prurigo / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000188:drug therapy
D013792:Thalidomide